Drug Type Small molecule drug |
Synonyms TQB3728 |
Target |
Mechanism IAP antagonists(Inhibitors of apoptosis (IAP) protein family antagonists), XIAP inhibitors(Inhibitor of apoptosis protein 3 inhibitors), cIAP1/cIAP2 inhibitors(cIAP1/cIAP2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Head and Neck Neoplasms | Phase 2 | CN | 19 Oct 2023 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 01 Jun 2023 | |
Advanced cancer | Phase 1 | CN | 27 Aug 2020 | |
Lymphoma | Phase 1 | CN | 27 Aug 2020 | |
Neoplasms | Preclinical | CN | 01 Jul 2019 | |
Neoplasms | Preclinical | CN | 01 Jul 2019 | |
Advanced Malignant Solid Neoplasm | Discovery | CN | 26 Oct 2020 | |
Hematologic Neoplasms | Discovery | CN | 26 Oct 2020 |
NCT04523285 (ASCO2024) Manual | Phase 1 | 23 | (gjigmnmyau) = Not observed yzipcvmshr (itguixpqwn ) View more | Negative | 24 May 2024 | ||
TQB3728 was given orally once a week, on a 28-day cycle |